MAM
KYMR icon

Martingale Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Martingale Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,621
Closed -$285K – 843
2023
Q1 		$285K Sell
9,621
-3
-0% -$97 0.01% 715
2022
Q4 		$240K Hold
9,624
– – ﹤0.01% 761
2022
Q3 		$210K Buy
+9,624
New +$254K ﹤0.01% 776

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Martingale Asset Management's KYMR Position: Q2 2023 in Review

Martingale Asset Management sold out of Kymera Therapeutics (KYMR) in Q2 2023, closing a stake of 9,621 shares — an estimated $285K sold.

Martingale Asset Management first reported a position in KYMR in Q3 2022 and held it in 3 quarters. The position peaked at $285K in Q1 2023. 128 funds tracked by Wall St. Rank hold KYMR as of Q2 2023.

  • Martingale Asset Management reported no remaining Kymera Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Martingale Asset Management sold 9,621 Kymera Therapeutics shares in Q2 2023, an estimated $285K.
  • Martingale Asset Management first reported a position in Kymera Therapeutics in Q3 2022 and held it in 3 quarters.
  • Martingale Asset Management's Kymera Therapeutics position peaked at $285K in Q1 2023.
  • 128 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2023.

Based on Martingale Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.